-+ 0.00%
-+ 0.00%
-+ 0.00%

Sandoz Partners With Fresenius Unit mAbxience On Licensing, Development, Manufacturing And Commercialization For An Emicizumab Biosimilar Candidate

Benzinga·09/18/2026 10:23:13
Listen to the news
  • Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.
  • The agreement is consistent with mAbxience's strategy of broadening patient access to high-quality biologic medicines through selected partnerships in global markets.